Applied Therapeutics Extends Tender Offer Again; 44.32% Shares Tendered
APLT is trading near its 52-week low of $0.09 (7.1% above the low).
Summary
Applied Therapeutics has extended its tender offer by Cycle Group Holdings for a second time, with 44.32% of shares tendered, still below the majority condition.
Key Events · M&A and Partnerships · APLT
-
Tender Offer Extended
The tender offer by AT2B, Inc., a subsidiary of Cycle Group Holdings, has been extended to January 29, 2026, from its previous expiration on January 28, 2026. This marks the second extension of the offer.
-
Tendered Shares Update
As of January 28, 2026, approximately 68.35 million shares, representing 44.32% of outstanding shares, have been validly tendered. This amount is still below the majority condition required for the offer to close.
-
Acquisition Terms Unchanged
The offer price remains $0.088 cash per share plus one non-tradeable contingent value right (CVR), with the CVR potentially yielding up to an additional $0.40 per share upon achievement of specified milestones.
Analysis · APLT · Life Sciences
This filing provides a critical update on the ongoing tender offer by Cycle Group Holdings for Applied Therapeutics. The offer has been extended for a second time, indicating difficulty in meeting the majority tender condition. While a significant portion of shares (44.32%) have been tendered, it remains below the required threshold for the acquisition to close. This continued delay and the current tender rate introduce uncertainty regarding the deal's completion, despite the board's prior recommendation.
At the time of this filing, APLT was trading at $0.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $0.09 to $1.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.